Dividend Assets Capital’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10M Buy
272,379
+2,525
+0.9% +$120K 2% 18
2025
Q4
$13.7M Sell
269,854
-40,847
-13% -$2.09M 2.62% 8
2025
Q3
$17.2M Buy
310,701
+48,339
+18% +$2.83M 3.02% 6
2025
Q2
$18.1M Sell
262,362
-3,825
-1% -$260K 3.29% 4
2025
Q1
$18.5M Buy
266,187
+51,572
+24% +$4.26M 3.5% 4
2024
Q4
$18.5M Buy
214,615
+6,395
+3% +$692K 3.58% 6
2024
Q3
$24.8M Buy
208,220
+2,401
+1% +$320K 4.74% 3
2024
Q2
$29.4M Buy
205,819
+2,877
+1% +$381K 5.99% 2
2024
Q1
$26.1M Buy
202,942
+6,763
+3% +$805K 5.49% 2
2023
Q4
$20.3M Sell
196,179
-11,443
-6% -$1.13M 3.99% 4
2023
Q3
$18.9M Sell
207,622
-12,996
-6% -$1.14M 3.92% 3
2023
Q2
$17.9M Sell
220,618
-21,500
-9% -$1.76M 3.67% 4
2023
Q1
$16.4M Hold
242,118
3.48% 4
2022
Q4
$16.4M Sell
242,118
-3,792
-2% -$222K 3.48% 4
2022
Q3
$12.3M Sell
245,910
-878
-0.4% -$47K 2.81% 6
2022
Q2
$13.8M Sell
246,788
-10,462
-4% -$581K 2.97% 5
2022
Q1
$14.3M Sell
257,250
-10,650
-4% -$547K 2.7% 5
2021
Q4
$15M Sell
267,900
-850
-0.3% -$46K 2.78% 6
2021
Q3
$12.9M Sell
268,750
-6,342
-2% -$307K 2.6% 7
2021
Q2
$11.5M Sell
275,092
-18,550
-6% -$719K 2.26% 11
2021
Q1
$9.9M Sell
293,642
-1,000
-0.3% -$35.6K 1.88% 13
2020
Q4
$10.3M Sell
294,642
-15,298
-5% -$529K 2% 12
2020
Q3
$10.8M Sell
309,940
-6,940
-2% -$231K 2.56% 8
2020
Q2
$10.4M Sell
316,880
-15,442
-5% -$493K 2.17% 10
2020
Q1
$10M Sell
332,322
-9,214
-3% -$274K 2.45% 10
2019
Q4
$9.88M Sell
341,536
-58,214
-15% -$1.61M 1.59% 15
2019
Q3
$10.3M Sell
399,750
-1,880
-0.5% -$47.5K 1.66% 15
2019
Q2
$10.3M Sell
401,630
-4,518
-1% -$112K 1.62% 13
2019
Q1
$10.6M Sell
406,148
-39,854
-9% -$979K 1.72% 12
2018
Q4
$10.3M Sell
446,002
-23,060
-5% -$512K 1.79% 10
2018
Q3
$11.1M Sell
469,062
-6,842
-1% -$167K 1.41% 18
2018
Q2
$11M Sell
475,904
-36,144
-7% -$859K 1.43% 18
2018
Q1
$12.6M Sell
512,048
-494,068
-49% -$13M 0.62% 53
2017
Q4
$27M Sell
1,006,116
-374,660
-27% -$9.53M 1.21% 38
2017
Q3
$33.2M Sell
1,380,776
-17,598
-1% -$398K 1.37% 34
2017
Q2
$30M Sell
1,398,374
-291,964
-17% -$5.89M 1.18% 41
2017
Q1
$29M Sell
1,690,338
-1,361,444
-45% -$23.7M 1.06% 43
2016
Q4
$54.7M Sell
3,051,782
-2,011,978
-40% -$36.5M 1.92% 23
2016
Q3
$105M Sell
5,063,760
-163,900
-3% -$4.06M 3.33% 1
2016
Q2
$141M Sell
5,227,660
-34,434
-0.7% -$944K 4.17% 1
2016
Q1
$143M Sell
5,262,094
-258,478
-5% -$6.92M 4.09% 1
2015
Q4
$160M Sell
5,520,572
-116
-0% -$3.21K 4.35% 1
2015
Q3
$150M Sell
5,520,688
-1,232
-0% -$34.9K 3.79% 1
2015
Q2
$151M Sell
5,521,920
-18,920
-0.3% -$532K 3.33% 1
2015
Q1
$148M Buy
5,540,840
+214,556
+4% +$4.94M 3.24% 1
2014
Q4
$113M Buy
5,326,284
+1,102,844
+26% +$24.6M 2.56% 11
2014
Q3
$101M Buy
4,223,440
+147,880
+4% +$3.4M 2.54% 10
2014
Q2
$94.1M Buy
4,075,560
+3,302
+0.1% +$72.9K 2.51% 9
2014
Q1
$92.9M Sell
4,072,258
-11,932
-0.3% -$254K 2.75% 7
2013
Q4
$75.5M Sell
4,084,190
-257,040
-6% -$4.48M 2.46% 13
2013
Q3
$73.5M Buy
4,341,230
+14,900
+0.3% +$251K 2.75% 6
2013
Q2
$67M Buy
+4,326,330
New +$72M 2.95% 5

Other funds holding NVO

Dividend Assets Capital's NVO Position: Q1 2026 in Review

Dividend Assets Capital increased its Novo Nordisk (NVO) stake by 0.94% in Q1 2026, buying an estimated $120K and bringing the position to 272,379 shares worth $10M. The position accounts for 2% of the portfolio, ranked #18.

Dividend Assets Capital first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $160M in Q4 2015. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Dividend Assets Capital held 272,379 shares of Novo Nordisk worth $10M as of Q1 2026.
  • Dividend Assets Capital bought 2,525 Novo Nordisk shares in Q1 2026, an estimated $120K.
  • Novo Nordisk made up 2% of Dividend Assets Capital's portfolio in Q1 2026, its #18 holding.
  • Dividend Assets Capital first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Dividend Assets Capital's Novo Nordisk position peaked at $160M in Q4 2015.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Dividend Assets Capital's 13F filing for Q1 2026, filed 28 Apr 2026.